Low-grade gliomas are among the most common primary brain tumors in childhood and can affect patients for life, which is why early diagnosis involving the tumor microenvironment is of significant importance. An international study published in 2025, in which the researchers used imaging mass cytometry to examine over 100 tumor samples at the single-cell level, revealed new therapeutic approaches with the potential combination of blocking the immune checkpoint receptor TIM-3 expressed on myeloid cells with inhibition of the MAPK signaling pathway.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Low-grade pediatric gliomas
Consideration of the tumor microenvironment opens up new treatment options
- Palliative care symptom and needs assessment.
What screening tools are helpful?
- Patient-centered rounds in medicine
Aligning care with the patient
- HIV: antiretroviral therapy (ART)
Single-tablet regimens support adherence
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- Vaccinations against viral respiratory infections
Influenza, Covid-19 and RSV – Update 2025
- GLP1-RA therapy
Improvement in either weight or HbA1c – but never both
- Suicide